Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer. “Dana has over two decades of operational expertise across cell therapy, gene therapy and biologics process development and chemistry, manufacturing, and controls (CMC), from Phase 1 through commercialization,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidia